Summary
Overall partial alignment: one claim supported, one unsupported, one partially supported, and one contradicted based on the provided label.
Category Scores
Accurate Statements
NERLYNX is indicated for extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer to follow adjuvant trastuzumab-based therapy.
Label section 1.1
Unsupported Statements
On July 17, 2017, the FDA approved neratinib.
Label sections provided do not mention any FDA approval date.
This indication is for adults who have completed trastuzumab-containing adjuvant therapy within the past year.
Label supports extended adjuvant therapy after trastuzumab-based therapy but does not specify a 1-year timeframe.
Contradictions
Low
AI Statement
This is the only FDA-approved indication for neratinib to date.
Label Reference
1.1, 1.2
Important Omissions
The label has a second indication (1.2) for advanced/metastatic HER2-positive breast cancer in combination with capecitabine, which is not referenced in the claims.
Importance:
Moderate
No explicit timeframe (e.g., within x years) is provided for the completion of trastuzumab-containing adjuvant therapy in the indication claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Assessment focuses on label claim alignment; no safety risk assessment performed.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Discrepancy regarding claims about the number of indications (1.1 and 1.2) and lack of date/timeframe for the approval.
Suggested Improvement
Clarify that neratinib has two labeled indications (extended adjuvant therapy 1.1 and advanced/metastatic therapy with capecitabine 1.2) and avoid implying a single indication; include any approval date if relevant and specify timeframe details if applicable.